Sumitomo Dainippon Pharma Oncology

Sumitomo Dainippon Pharma Oncology pertence à Sumitomo Chemical.

Sumitomo Chemical é uma das ...

• Forbes Global 2000 (#1009);
• Nikkei 225;
• Topix.

Sumitomo Chemical é uma empresa listada sob o símbolo 4005 (JP).

Sumitomo Chemical tem presença direta em 6 países.

Sumitomo Chemical possui 28 subsidiárias incluindo Asahi Chemical, Ciox Health e Covant Therapeutics.

Eles estão dentro:

• Biotecnologia55%
• Produtos Químicos24%
• Outro21%

Veja o organograma con seus 4 executivos principais

Biografias mais buscadas da Sumitomo Dainippon Pharma Oncology

• Steven Warner, Senior Vice President and Head of Translational Res...
• Jatin Shah, Chief Oncology Development Officer
• Masashi Murata, Senior Vice Presiden and Head of Program Management

Criar um alerta
para seguir os movimentos de executivos da Sumitomo Dainippon Pharma Oncology.

Sumitomo Chemical possui 2.285 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).

Popular M&A news in Biotecnologia

• Karius acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 3 de maio de 2024).
• Transcarent acaba de anunciar uma arrecadação de fundos de 126 milhões de dólares. (publicado em 2 de maio de 2024).
• WindRose Health Investors has announced the acquisition of SubjectWell  (publicado em 2 de maio de 2024).

Outros contatos sugeridos na indústria do Biotecnologia

• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics
• Vik Bajaj - Director da Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board da Sensorion

Saiba mais sobre a indústria do Biotecnologia >

Últimos comunicados de imprensa de Sumitomo Dainippon Pharma Oncology

• Sumitomo Pharma Announces Availability of ORGOVYX® (relugolix) in Canada, the First and Only Oral Androgen Deprivation Therapy Treatment for Men with Advanced Prostate Cancer
• Sumitomo Pharma and Pfizer Canada Announce Availability of MYFEMBREE® in Canada
• Sumitomo Pharma America and Actress Holly Robinson Peete Extend Time To Go™ Campaign to Empower People with Overactive Bladder
• Sumitomo Pharma Presents Encouraging New Data on DSP-5336 Clinical Activity at the American Society of Hematology Annual Meeting
• Sumitomo Pharma America Newsroom - News ReleasesBack ButtonFilter Button
• Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid CongressBack ButtonFilter Button
• Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-1287, an Investigational Oral CDK9 Inhibitor for the Treatment of Ewing Sarcoma
• Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitomo Pharma Oncology, to Combine and Form Sumitomo Pharma America
• Sumitomo Pharma Oncology Presents Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at American Society of Hematology 2022 Annual Meeting & Exposition
• Sumitomo Pharma Oncology to Present Preliminary Clinical Data Evaluating Investigational Agent TP-3654 at the 64th ASH Annual Meeting & Exposition
• View more press releases Close

Redes sociais sobre Sumitomo Dainippon Pharma Oncology

• Sumitomo Dainippon Pharma Oncology na Wikipedia, Google News e Yahoo Finance
• Sumitomo Dainippon Pharma Oncology na LinkedIn, Twitter e YouTube

Contate seus executivos por e-mail agora, incluindo Jatin Shah

Ligue para a Sumitomo Dainippon Pharma Oncology em +1 617...

Veja o organograma

Register to receive your alert

Relatório um erro